{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:13:29Z","timestamp":1763018009395,"version":"3.37.3"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Doravirine (DOR) demonstrated noninferior efficacy to darunavir plus ritonavir (DRV+r) and efavirenz (EFV) in 2 ongoing phase 3 trials: DRIVE-FORWARD (NCT02275780) and DRIVE-AHEAD (NCT02403674).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This prespecified analysis pooled efficacy data through the first 48 weeks of DRIVE-FORWARD and DRIVE-AHEAD from the DOR groups (DOR\/lamivudine [3TC]\/tenofovir disoproxil fumarate [TDF] or DOR [100 mg daily] with emtricitabine [FTC]\/TDF or abacavir [ABC]\/3TC [n = 747]) compared with DRV+r (800\/100 mg daily) with FTC\/TDF or ABC\/3TC (n = 383) or EFV\/FTC\/TDF (600\/200\/300 mg daily; n = 364). Efficacy assessments included the proportion of participants with human immunodeficiency virus type 1 (HIV-1) RNA &amp;lt;50 copies\/mL and change in CD4+ T-cell count.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At week 48, DOR demonstrated noninferior efficacy to DRV+r and EFV, with 84.1% of DOR-treated participants achieving HIV-1 RNA &amp;lt;50 copies\/mL compared with 79.9% of the DRV+r and 80.8% of the EFV groups. Results were similar across demographic\/prognostic subpopulations, including baseline plasma HIV-1 RNA, gender, race, and HIV-1 subtype. Mean increases from baseline in CD4+ T-cell count through 48 weeks were 195.5 cells\/mm3 for DOR, 185.6 cells\/mm3 for DRV+r, and 188.4 cells\/mm3 for EFV\/FTC\/TDF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>DOR, as a single entity (in combination with other antiretroviral agents) and as a fixed-dose combination (DOR\/3TC\/TDF), demonstrated noninferior efficacy to DRV+r and EFV as assessed by the proportion of HIV-1-infected, treatment-naive adults with HIV-1 RNA &amp;lt;50 copies\/mL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trials Registration<\/jats:title><jats:p>NCT02275780 and NCT02403674.<\/jats:p><\/jats:sec>","DOI":"10.1093\/cid\/ciz424","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T19:33:08Z","timestamp":1558553588000},"page":"1344-1352","source":"Crossref","is-referenced-by-count":11,"title":["Once-daily Doravirine in Human Immunodeficiency Virus Type 1\u2013Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis"],"prefix":"10.1093","volume":"70","author":[{"given":"Chloe","family":"Orkin","sequence":"first","affiliation":[{"name":"Queen Mary University, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Molina","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Saint-Louis Hospital, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Lombaard","sequence":"first","affiliation":[{"name":"Josha Research, Bloemfontein, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin","family":"DeJesus","sequence":"first","affiliation":[{"name":"Orlando Immunology Center, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Rodgers","sequence":"first","affiliation":[{"name":"Merck & Co., Inc, Kenilworth, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushma","family":"Kumar","sequence":"first","affiliation":[{"name":"Merck & Co., Inc, Kenilworth, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Martin","sequence":"first","affiliation":[{"name":"Merck & Co., Inc, Kenilworth, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Hanna","sequence":"first","affiliation":[{"name":"Merck & Co., Inc, Kenilworth, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carey","family":"Hwang","sequence":"first","affiliation":[{"name":"Merck & Co., Inc, Kenilworth, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,5,23]]},"reference":[{"key":"2020031707173074000_CIT0001","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2005.05.001","article-title":"Antiviral drug discovery and development: where chemistry meets with biomedicine","volume":"67","author":"De Clercq","year":"2005","journal-title":"Antiviral Res"},{"key":"2020031707173074000_CIT0002","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2009.05.007","article-title":"Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead","volume":"138","author":"Sosnik","year":"2009","journal-title":"J Control Release"},{"key":"2020031707173074000_CIT0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7448\/IAS.16.1.18567","article-title":"Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability","volume":"16","author":"Usach","year":"2013","journal-title":"J Int AIDS Soc"},{"key":"2020031707173074000_CIT0004","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1345\/aph.1M359","article-title":"Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents","volume":"44","author":"Adams","year":"2010","journal-title":"Ann Pharmacother"},{"author":"Janssen Therapeutics","key":"2020031707173074000_CIT0005"},{"author":"Janssen Therapeutics","key":"2020031707173074000_CIT0006"},{"key":"2020031707173074000_CIT0007","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1128\/AAC.02403-13","article-title":"In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor","volume":"58","author":"Lai","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020031707173074000_CIT0008","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/AAC.04201-14","article-title":"In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways","volume":"59","author":"Feng","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"author":"Merck & Co Inc","key":"2020031707173074000_CIT0009"},{"author":"Merck & Co Inc","key":"2020031707173074000_CIT0010"},{"key":"2020031707173074000_CIT0011","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3851\/IMP2920","article-title":"Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects","volume":"20","author":"Anderson","year":"2015","journal-title":"Antivir Ther"},{"key":"2020031707173074000_CIT0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01364-16","article-title":"Results of a doravirine-atorvastatin drug-drug interaction study","volume":"61","author":"Khalilieh","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020031707173074000_CIT0013","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40261-017-0512-5","article-title":"The effect of food on doravirine bioavailability: results from two pharmacokinetic studies in healthy subjects","volume":"37","author":"Behm","year":"2017","journal-title":"Clin Drug Investig"},{"article-title":"Co-administration of doravirine with an aluminum\/magnesium-containing antacid or pantoprazole, a proton-pump inhibitor, does not have a clinically meaningful effect on doravirine pharmacokinetics (abstract MOPEB0334).","year":"2017","author":"Khalilieh","key":"2020031707173074000_CIT0014"},{"key":"2020031707173074000_CIT0015","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"2020031707173074000_CIT0016","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy540","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial","author":"Orkin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020031707173074000_CIT0017","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/QAD.0b013e32830285fb","article-title":"Efficacy and safety of once-daily darunavir\/ritonavir versus lopinavir\/ritonavir in treatment-naive HIV-1-infected patients at week 48","volume":"22","author":"Ortiz","year":"2008","journal-title":"AIDS"},{"key":"2020031707173074000_CIT0018","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"2020031707173074000_CIT0019","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet"},{"key":"2020031707173074000_CIT0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial","volume":"378","author":"Cohen","year":"2011","journal-title":"Lancet"},{"key":"2020031707173074000_CIT0021","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/QAI.0000000000000017","article-title":"Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine\/emtricitabine\/tenofovir DF or efavirenz\/emtricitabine\/tenofovir DF in the STaR study (GS-US-264-0110)","volume":"65","author":"Porter","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020031707173074000_CIT0022","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e31823df4da","article-title":"Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis","volume":"59","author":"Rimsky","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020031707173074000_CIT0023","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M14-1084","article-title":"Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial","volume":"161","author":"Lennox","year":"2014","journal-title":"Ann Intern Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz424\/31108897\/ciz424.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/7\/1344\/32921280\/ciz424.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/7\/1344\/32921280\/ciz424.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T05:10:12Z","timestamp":1607922612000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/70\/7\/1344\/5497916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,23]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,5,23]]},"published-print":{"date-parts":[[2020,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz424","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"type":"print","value":"1058-4838"},{"type":"electronic","value":"1537-6591"}],"subject":[],"published-other":{"date-parts":[[2020,4,1]]},"published":{"date-parts":[[2019,5,23]]}}}